BiotechTube

HJB647 low dose + HJB647 high dose

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heart Failure With Reduced Ejection Fraction

Conditions

Heart Failure With Reduced Ejection Fraction

Trial Timeline

Mar 19, 2026 → Sep 21, 2026

NCT ID
NCT07465653

About HJB647 low dose + HJB647 high dose

HJB647 low dose + HJB647 high dose is a phase 1 stage product being developed by Novartis for Heart Failure With Reduced Ejection Fraction. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07465653. Target conditions include Heart Failure With Reduced Ejection Fraction.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure With Reduced Ejection Fraction were approved

Approved (20) Terminated (2) Active (0)
✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
✅ConivaptanAstellas PharmaApproved
✅RegadenosonAstellas PharmaApproved
✅Regadenoson + GadoliniumAstellas PharmaApproved
✅regadenosonAstellas PharmaApproved
✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07465653Phase 1Recruiting

Competing Products

20 competing products in Heart Failure With Reduced Ejection Fraction

See all competitors
ProductCompanyStageHype Score
mRNA-0184ModernaPhase 1
0
IV diureticNuwellisPre-clinical
16
IV Loop DiureticsNuwellisPre-clinical
23
Stepped pharmacologic careNuwellisPhase 3
30
IV Loop Diuretics (LD)NuwellisPre-clinical
8
TRV120027 + Normal SalineTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
TRV120027 + PlaceboTrevenaPhase 1/2
22
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
INXN-4001PrecigenPhase 1
23
LY3461767 + PlaceboEli LillyPhase 1
29
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
43
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
32
OlmesartanDaiichi SankyoPhase 3
40
Carperitide + PlaceboDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
22
RegadenosonAstellas PharmaPhase 1
29
Advagraf + PrografAstellas PharmaPhase 2
35